NCT04982549 2021-08-06
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Shandong Cancer Hospital and Institute
Phase 2 Unknown
Shandong Cancer Hospital and Institute
Intergroupe Francophone de Cancerologie Thoracique
The First Affiliated Hospital of Guangzhou Medical University
Asan Medical Center
Zhejiang Cancer Hospital
University of Saskatchewan
West Japan Thoracic Oncology Group